Back

The ARDVAARC study: real-world outcomes and the utility of bleeding risk scores in patients who require anticoagulation following percutaneous coronary intervention (PCI)

28 August 2018 (14:00 - 18:00)
Organised by:
Congress Presentation Part of: Poster Session 7 - Risk scores at coronary revascularisation Adjunctive Pharmacotherapy ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor Matthew Li Kam Wa

Guy's and St Thomas' NHS Trust Foundation Trust, London (United Kingdom of Great Britain & Northern Ireland)

9 More presentations in this session

Presentation thumbnail
Doctor M. Shiba (Tokyo, JP)
Abstract
Presentation thumbnail
Doctor L. Wang (Singapore, SG)
Abstract Slides
Presentation thumbnail
Doctor M. Brockmeyer (Duesseldorf, DE)
Abstract Slides
Presentation thumbnail
Doctor F. Abcha (Tunis, TN)
Abstract Slides
Presentation thumbnail
Associate Professor L. Di Serafino (Naples, IT)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 7 - Risk scores at coronary revascularisation

The Event

Event poster

ESC Congress 2018

28 August 2018 14:00 CET
You may be interested in
thumbnail
Congress Presentation
A patient with recent non-ST elevation myocardial infarction and percutaneous coronary intervention requiring cancer surgery: what do the guidelines say?
thumbnail
Congress Session
2023 ESC Guidelines for the Management of Acute Coronary Syndromes
thumbnail
Congress Session
Adjunct pharmacology in PCI: beyond antiplatelet therapy, the next chapter

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources